Article
Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant.
Molecular endocrinology (Baltimore, Md.) - 1 May 2006
Butler Lisa M, Centenera Margaret M, Neufing Petra J, Buchanan Grant, Choong Catherine S Y, Ricciardelli Carmela, Saint Kathleen, Lee Melissa, Ochnik Aleksandra, Yang Miao, Brown Michael P, Tilley Wayne D
Abstract excerpt
There is increasing evidence that sensitization of the androgen receptor (AR) signaling pathway contributes to the failure of androgen ablation therapy for prostate cancer, and that direct targeting of the AR may be a useful therapeutic approach. To better understand how AR function could be abrogated in prostate cancer cells, we have developed a series of putative dominant-negative variants of the human AR,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.